Long-term conventional interferon alpha in combination with lamivudine for chronic hepatitis B: Data from Turkey

Basit Öğe Kaydı
dc.contributor.authorYilmaz, Serif
dc.contributor.authorBayan, Kadim
dc.contributor.authorDursun, Mehmet
dc.contributor.authorCanoruc, Fikri
dc.contributor.authorPasa, Semir
dc.contributor.authorSaka, Guenay
dc.date.accessioned2024-04-24T17:37:37Z
dc.date.available2024-04-24T17:37:37Z
dc.date.issued2007
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground/Aims: Standard interferon or lamivudine monotherapy has been shown to induce a low response rate in patients with chronic hepatitis B infection. Genotype D represents almost the whole of chronic HBV infection of Turkish population. The aim of this study was to evaluate the efficacy and safety of the long-term interferon-alpha plus lamivudine on these patients, and thereafter the co-effect of maintenance therapy by lamivudine. Methodology: This prospective study was carried out between the late 1999 and 2005. A total of 37 (24 HBeAg-positive and 13 HBeAg-negative) patients were enrolled in the study. These patients received standard interferon-alpha (9/10 MU) three times sc. a week plus lamivudine 100mg po. daily, for 52 weeks. After the interferon discontinuation, lamivudine monotherapy was assigned to be given until 4-6 months after the occurrence of HBeAg seroconversion in the HBeAg-positive patients and at least three years in HBeAg-negative patients. Response-1 was defined as the response at the end of combination therapy at the 52nd week, and Response-2 as response at the end of the follow-up period under lamivudine monotherapy. An intention-to-treat analysis was performed. Results: Patients' follow-up ranged between 7-67 months, with a mean duration of 29.64 +/- 14.01 months. Twenty-six patients (70.3%) had a Response-1, both virological and biochemical. A biochemical Response-2 was achieved in 24 patients (64.9%), while virological Response-2 in 17 (45.9%). Response-1 and Response-2 were similar between HBeAg-positive and HBeAg-negative patients (p=0.262 and p=0.734, respectively). HBeAg seroconversion was achieved only in 8 (33.3%) of HBeAg-positive patients. Clinical resistance to lamivudine developed only in 9 (24.3%) of the patients. Decompensation or hepatocellular carcinoma did not observe in any case. Conclusions: This study showed the efficacy of the 'long-term' anti-viral maintenance along with the combination therapy in genotype D predominant chronic hepatitis B patients. A low clinical resistance rate to lamivudine was achieved.en_US
dc.identifier.endpage2352en_US
dc.identifier.issn0172-6390
dc.identifier.issue80en_US
dc.identifier.pmid18265662
dc.identifier.scopus2-s2.0-37749052791
dc.identifier.scopusqualityN/A
dc.identifier.startpage2348en_US
dc.identifier.urihttps://hdl.handle.net/11468/21072
dc.identifier.volume54en_US
dc.identifier.wosWOS:000251892800036
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherH G E Update Medical Publishing S Aen_US
dc.relation.ispartofHepato-Gastroenterology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLong-Term Combination Treatmenten_US
dc.subjectHepatitis Ben_US
dc.titleLong-term conventional interferon alpha in combination with lamivudine for chronic hepatitis B: Data from Turkeyen_US
dc.titleLong-term conventional interferon alpha in combination with lamivudine for chronic hepatitis B: Data from Turkey
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu